Important news

Exciting Milestone for Gongwin Biopharm Co., Ltd.: Successful OTC and Share Issuance

Gongwin Biopharm Co., Ltd. is pleased to announce a significant achievement, marking a new chapter in our growth:

• Completion of OTC Process:
  Gongwin Biopharm has successfully completed its OTC (Over-the-Counter) process, with 127,506,100 shares now available for trade under the stock code "6617" and the abbreviation "共信-KY" (Gongwin).
• New Share Issuance and Fundraising:
  We have issued 14.17 million new shares, raising a total of USD 61.7 million in capital, which will further support our company's continued growth and innovation.
• First Listing and Trading Conditions:
  This marks our company's initial public offering (IPO) on the OTC market as a biotech and medical company. For the first five trading days from June 18, 2024, there will be no price fluctuation limits on the stock.
• Registered Location:
  Gongwin Biopharm Holdings Co., Ltd. is registered in the Cayman Islands, and we continue to adhere to all regulatory standards in both our listing and trading.
• Transition from Emerging Stock Market:
  Prior to this milestone, Gongwin's stock was traded as an emerging stock. With this successful transition, trading under the emerging stock category has been terminated effective June 18, 2024.
• Non-Physical Share Issuance:
  Gongwin Biopharm’s shares are issued in a non-physical form, aligned with modern securities practices.
• Legal Representation:
  Mr. Morrice Lin serves as the company's legal representative for litigation or non-litigation matters within Taiwan.

We extend our heartfelt thanks to all our supporters and look forward to leveraging this capital for continued success in the biotech field.